Sign in
TERN Stock Price, Chart, Stats & News
Terns Pharmaceuticals, Inc.
Save
4.77B
Market cap
–
Current P/E
–
Forward P/E
TERN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.25% |
ROA | -31.31% |
ROE | -29.95% |
D/E | 0.00x |
Interest coverage ratio | – |
TERN valuation
P/E | – |
P/S | – |
P/B | 17.08x |
P/CF | -62.47x |
P/FCF | -61.36x |
P/OCF | -62.47x |
PEG | -53.44x |
EV multiple | -48.44x |
About
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH.
Similar securities
Based on sector and market capitalization
Report issue